ArticleScientific reports2026
Decoding the therapeutic promise of Solanum trilobatum in oral submucous fibrosis: a network pharmacology, docking, and bioactivity study.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral submucous fibrosis (OSF) is a chronic, progressive, and potentially malignant disorder with limited therapeutic options. This study explored the therapeutic potential of Solanum trilobatum (S.trilobatum) using a network pharmacology and molecular docking approach. 5 phytochemicals from S. trilobatum were identified with favorable drug-likeness, good gastrointestinal absorption, and low predicted toxicity. Target analysis for 5 phytochemicals revealed 24 potential targets associated with OSF. The 24 targets were enriched in various pathways, and PPI analysis of the targets using MCODE identified six hub genes, namely PLG, ABCB1, PTGS2, HMGCR, NOS2, and MAPK3. Druggability analysis further confirmed that the identified hub genes could serve as potential therapeutic targets. ProteomicsDB analysis revealed the expression of the hub genes in the oral cavity. Docking confirmed that Solasodine exhibited significant binding affinities with the six targets, comparable to or stronger than the control drug dexamethasone, thereby suggesting their multitargeting potential. Molecular dynamics (MD) simulation (100 ns) was performed for Solasodine, as it exhibited the highest binding affinity across all six targets, and the simulation confirmed the formation of a stable ligand-protein complex. The bioactivity analysis further confirmed the therapeutic potential of the phytochemicals. This study provides preliminary evidence that S. trilobatum phytochemicals may function as multitarget modulators in OSF through the regulation of key genes. In vitro assays demonstrated that S. trilobatum leaf extract exhibited dose-dependent antioxidant (DPPH and H
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.